Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Laetsch, Theodore W  [Clear All Filters]
2023
Eylon M, Prabhu S, John S, King MJM, Bhatt D, Curran KJ, Erickson C, Karras NA, Phillips CL, Satwani P, et al. Mediport use as an acceptable standard for CAR T cell infusion. Front Immunol. 2023;14:1239132.
McNerney KO, Moskop A, Winestone LE, Baggott C, Talano J-A, Schiff D, Rossoff J, Modi A, Verneris MR, Laetsch TW, et al. Practice preferences for consolidative HSCT following tisagenlecleucel in children and young adults with B-ALL. Transplant Cell Ther. 2023.
Barsan V, Li Y, Prabhu S, Baggott C, Nguyen K, Pacenta H, Phillips CL, Rossoff J, Stefanski H, Talano J-A, et al. Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns. EClinicalMedicine. 2023;65:102268.
2022
Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, Baruchel A, Boyer M, de Moerloose B, Qayed M, et al. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. J Clin Oncol. 2022:JCO2200642.
2019
Laetsch TW, Myers GDouglas, Baruchel A, Dietz AC, Pulsipher MA, Bittencourt H, Buechner J, de Moerloose B, Davis KL, Nemecek E, et al. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncol. 2019.
2018
Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, et al. Clinical utilization of Chimeric Antigen Receptors T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) - an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transpl. Biol Blood Marrow Transplant. 2018.